SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
July 2024
Commission File
Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨ No
x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
|
Date: July 18, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
July 18, 2024
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Press Release
Please find enclosed a Press Release on “Dr.
Reddy’s signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan, a novel gastrointestinal drug, in
India”.
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Encl: As above
|
CONTACT |
DR. REDDY'S LABORATORIES LTD. |
Investor relationS |
Media relationS |
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034, Telangana, India. |
RICHA PERIWAL
richaperiwal@drreddys.com
|
USHA IYER
ushaiyer@drreddys.com |
Dr. Reddy’s
signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan, a novel gastrointestinal drug, in India
Hyderabad India; July 18th, 2024
– Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together
referred to as “Dr. Reddy’s”), today announced that it has entered into a non-exclusive patent licensing agreement with
Takeda Pharmaceutical Company Limited (“Takeda”) to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally
active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy’s
will market Vonoprazan tablets under its own trademark VONO™ to be available in two strengths, 10mg and 20mg.
Acid
Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India.
A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59
age group, with heart burn and epigastric pain as common symptoms1.
M.V. Ramana, CEO – Branded Markets (India
& Emerging Markets), Dr. Reddy’s, said, “For over three decades, patients and healthcare professionals have trusted
our products in the gastrointestinal segment including well-known brands such as Omez®, Razo™ and others. Leveraging our expertise
in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (Vono™) available to patients in India. The non-exclusive
patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through
strategic collaborations to meet unmet needs and enhance standard of care."
About Vonoprazan:
Vonoprazan
is the first-in-class Potassium Competitive Acid blocker (PCAB), which suppresses the gastric acid secretion by inhibiting the proton
pump potassium exchange. Compared to the traditional acid suppressing molecules like PPIs, Vonoprazan has unique attributes like Complete
proton pump inhibition with 1st dose, longer duration of action resulting in effective control of Nocturnal Acid Breakthrough and meal
independent dosing. Vonoprazan is proven to be effective and approved for the treatment of reflux esophagitis, gastric ulcer, duodenal
ulcer, prevention of reoccurrence of gastric ulcer or duodenal ulcer during low-dose aspirin administration or NSAIDs administration,
as an adjunct to Helicobacter pylori (H. pylori) eradication associated with: Gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic
thrombocytopenic purpura, the stomach after endoscopic resection of early stage cancer or Helicobacter Pylori gastritis2.
| 1 | https://www.ijbcp.com/index.php/ijbcp/article/view/178/162 |
| 2 | https://doi.org/10.1053/j.gastro.2018.01.018 and Prescribing information of Vonoprazan |
About Dr. Reddy’s: Dr. Reddy’s
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,
India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good
Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars
and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep
science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter
of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high
in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and
involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general
economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels
and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition
and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the
impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets
addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics
or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings
with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information
contained herein.
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Oct 2023 to Oct 2024